PMC8460752_01
Timeline of the clinical course.
fpsyt-12-728265-g0001.jpg
PMC8460752_01_fpsyt-12-728265-g0001.jpg
F1
Figure 1 shows the timeline of the clinical course. SPECT with 99mTc-ethylcysteinate dimer was performed before the beginning of ECT (in 1 month after admission) (A) and after the end of ECT (B) (in 4 months after admission) (Figure 1).
SPECT images before ECT (A, upper) and after ECT (B, lower).
fpsyt-12-728265-g0002.jpg
PMC8460752_01_fpsyt-12-728265-g0002.jpg
F2
Figures 2A,B show SPECT images before ECT (A) and after ECT (B).
Reduction of rCBF: before ECT (A, left), after ECT (B, center), and difference of rCBF before and after ECT (regions where rCBF reduction improved) (C, right).
fpsyt-12-728265-g0003.jpg
PMC8460752_01_fpsyt-12-728265-g0003.jpg
F3
Figures 3A,B show the reduction in rCBF before ECT (A) and after ECT (B). Figure 3C shows changes in rCBF reduction on SPECT before and after ECT (regions where rCBF reduction improved). The decrease in rCBF in the middle frontal gyrus and parietal lobe before ECT was ameliorated after ECT (Figures 3A-C).
Increase of rCBF before ECT (A, left), after ECT (B, center), and difference of rCBF before and after ECT (regions where rCBF increase improved) (C, right).
fpsyt-12-728265-g0004.jpg
PMC8460752_01_fpsyt-12-728265-g0004.jpg
F4
Figures 4A,B show the increase in rCBF before ECT (A) and after ECT (B). Figure 4C shows changes in rCBF increase on SPECT before and after ECT (regions where rCBF increase improved). The increase in rCBF in the thalamus, fusiform gyrus, and cerebellum before ECT approached normal levels after ECT (Figures 4A-C).